一名肾移植患者出现的依维莫司相关性口腔炎。
Everolimus-associated stomatitis in a patient who had renal transplant.
作者信息
Ji Yisi D, Aboalela Ali, Villa Alessandro
机构信息
Harvard School of Dental Medicine, Boston, Massachusetts, USA.
Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.
出版信息
BMJ Case Rep. 2016 Oct 19;2016:bcr2016217513. doi: 10.1136/bcr-2016-217513.
Abstract
Everolimus is used as an immunosuppressant in renal allograft transplant rejection and in metastatic breast cancer treatment. One side effect of everolimus is stomatitis, referred to as mammalian target of rapamycin inhibitor-associated stomatitis. This side effect can affect treatment course and contribute to discontinuation of therapy or dose reduction, previously reported in the treatment of metastatic breast cancer. Here, we present a case of everolimus-associated stomatitis with a novel management method with intralesional triamcinolone that allows for continuous course of everolimus.
摘要
依维莫司被用作肾移植排斥反应的免疫抑制剂以及转移性乳腺癌的治疗药物。依维莫司的一个副作用是口腔炎，称为雷帕霉素抑制剂相关口腔炎。这种副作用会影响治疗进程，并导致治疗中断或剂量减少，此前在转移性乳腺癌治疗中已有报道。在此，我们报告一例依维莫司相关性口腔炎病例，采用病灶内注射曲安奈德的新管理方法，使依维莫司能够持续使用。
相似文献
1
Everolimus-associated stomatitis in a patient who had renal transplant.一名肾移植患者出现的依维莫司相关性口腔炎。
BMJ Case Rep. 2016 Oct 19;2016:bcr2016217513. doi: 10.1136/bcr-2016-217513.
2
New drugs, new challenges for dermatologists: mucocutaneous ulcers secondary to everolimus.新药给皮肤科医生带来新挑战：依维莫司继发的皮肤黏膜溃疡
An Bras Dermatol. 2015 May-Jun;90(3 Suppl 1):165-7. doi: 10.1590/abd1806-4841.20153672.
3
Evaluation of Miracle Mouthwash plus Hydrocortisone Versus Prednisolone Mouth Rinses as Prophylaxis for Everolimus-Associated Stomatitis: A Randomized Phase II Study.评价 Miracle Mouthwash 联合 hydrocortisone 与 prednisolone 漱口液预防依维莫司相关性口腔黏膜炎的随机Ⅱ期研究。
Oncologist. 2019 Sep;24(9):1153-1158. doi: 10.1634/theoncologist.2018-0340. Epub 2019 Mar 4.
4
Random Allocated Study of Wrapping Oblate for Prevention of Everolimus-associated Stomatitis in Patients With Metastatic Renal Cell Carcinoma.
Anticancer Res. 2019 Jul;39(7):3937-3944. doi: 10.21873/anticanres.13546.
5
Late Pulmonary Toxicity Associated With Everolimus in a Renal Transplant Patient and Review of the Literature.肾移植患者中与依维莫司相关的迟发性肺毒性及文献综述
Exp Clin Transplant. 2018 Aug;16(4):491-494. doi: 10.6002/ect.2015.0257. Epub 2016 Mar 21.
6
Stomatitis Associated With Use of mTOR Inhibitors: Implications for Patients With Invasive Breast Cancer.与mTOR抑制剂使用相关的口腔炎：对浸润性乳腺癌患者的影响
Clin J Oncol Nurs. 2015 Aug;19(4):468-74. doi: 10.1188/15.CJON.468-474.
7
Everolimus-Related Chylothorax: A Rare Case Report.依维莫司相关性乳糜胸：一例罕见病例报告。
Exp Clin Transplant. 2024 Jun;22(6):471-474. doi: 10.6002/ect.2023.0252.
8
Breast cancer patients have increased risk of developing mTOR inhibitor-associated stomatitis.乳腺癌患者发生 mTOR 抑制剂相关性口腔炎的风险增加。
Oral Dis. 2018 Mar;24(1-2):207-209. doi: 10.1111/odi.12771.
9
Recommendations of everolimus use in liver transplant.依维莫司在肝移植中的应用推荐。
Gastroenterol Hepatol. 2017 Nov;40(9):629-640. doi: 10.1016/j.gastrohep.2017.05.008. Epub 2017 Jul 23.
10
引用本文的文献
1
A New Hypothesis Describing the Pathogenesis of Oral Mucosal Injury Associated with the Mammalian Target of Rapamycin (mTOR) Inhibitors.一种描述与雷帕霉素哺乳动物靶点（mTOR）抑制剂相关的口腔黏膜损伤发病机制的新假说。
Cancers (Basel). 2023 Dec 22;16(1):68. doi: 10.3390/cancers16010068.
2
Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients.口腔炎与依维莫司：对8201例患者的当前文献综述
Onco Targets Ther. 2019 Nov 14;12:9669-9683. doi: 10.2147/OTT.S195121. eCollection 2019.
3
Pathological Characteristics of Periodontal Disease in Patients with Chronic Kidney Disease and Kidney Transplantation.慢性肾脏病和肾移植患者牙周病的病理特征。
Int J Mol Sci. 2019 Jul 11;20(14):3413. doi: 10.3390/ijms20143413.
4
Oral administration of salmon cartilage proteoglycan extends the survival of allografts in mice.口服鲑鱼软骨蛋白聚糖可延长小鼠同种异体移植物的存活时间。
Biomed Rep. 2018 Jan;8(1):37-40. doi: 10.3892/br.2017.1011. Epub 2017 Nov 2.
5
Use of everolimus in liver transplantation.依维莫司在肝移植中的应用。
World J Hepatol. 2017 Aug 18;9(23):990-1000. doi: 10.4254/wjh.v9.i23.990.
本文引用的文献
1
Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice.雷帕霉素靶蛋白抑制剂所致口腔黏膜损伤：病理生物学新观点及其对临床实践的影响
Cancer Med. 2016 Aug;5(8):1897-907. doi: 10.1002/cam4.761. Epub 2016 Jun 23.
2
Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy.依维莫司临床研究中口腔炎的荟萃分析：发生率及其与疗效的关系。
Ann Oncol. 2016 Mar;27(3):519-25. doi: 10.1093/annonc/mdv595. Epub 2016 Jan 11.
3
Fewer cytomegalovirus complications after kidney transplantation by de novo use of mTOR inhibitors in comparison to mycophenolic acid.与霉酚酸相比，肾移植后重新使用mTOR抑制剂可减少巨细胞病毒并发症。
Transpl Infect Dis. 2016 Feb;18(1):79-88. doi: 10.1111/tid.12494. Epub 2016 Feb 3.
4
mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.三名接受依维莫司治疗的癌症患者发生的mTOR抑制剂相关口腔炎（mIAS）。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2015 Jan;119(1):e13-9. doi: 10.1016/j.oooo.2014.08.023. Epub 2014 Sep 16.
5
Everolimus in liver transplantation.
Curr Opin Organ Transplant. 2014 Dec;19(6):578-82. doi: 10.1097/MOT.0000000000000127.
6
Mammalian target of rapamycin inhibitor-associated stomatitis.雷帕霉素靶蛋白抑制剂相关性口腔炎。
Future Oncol. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141.
7
Decreased incidence of cytomegalovirus infection with sirolimus in a post hoc randomized, multicenter study in lung transplantation.在后设随机、多中心肺移植研究中，西罗莫司降低巨细胞病毒感染的发生率。
J Heart Lung Transplant. 2013 Jul;32(7):701-6. doi: 10.1016/j.healun.2013.04.010. Epub 2013 May 7.
8
Oral ulcers in patients with advanced breast cancer receiving everolimus: a case series report on clinical presentation and management.晚期乳腺癌患者接受依维莫司治疗后出现口腔溃疡：临床特征和处理的病例系列报告。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Aug;116(2):e110-6. doi: 10.1016/j.oooo.2013.02.022. Epub 2013 May 3.
9
Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial.依维莫司治疗结节性硬化症相关的血管平滑肌脂肪瘤或散发性淋巴管平滑肌瘤病（EXIST-2）：一项多中心、随机、双盲、安慰剂对照试验。
Lancet. 2013 Mar 9;381(9869):817-24. doi: 10.1016/S0140-6736(12)61767-X.
10
Is cytomegalovirus prophylaxis dispensable in patients receiving an mTOR inhibitor-based immunosuppression? a systematic review and meta-analysis.接受 mTOR 抑制剂为基础的免疫抑制治疗的患者中，巨细胞病毒预防是否可以省略？一项系统评价和荟萃分析。
Transplantation. 2012 Dec 27;94(12):1208-17. doi: 10.1097/TP.0b013e3182708e56.
Zotero 插件